FDA approved AstraZeneca's baxdrostat (Baxfendy) on May 18, 2026 — the first aldosterone synthase inhibitor for hypertension. Here's what...

NewGenIVF invests $2M in K25.ai prediction market at $100M valuation, with option for $10M more and board expansion across...

Tevogen Bio evaluates management services organization acquisition as part of infrastructure expansion strategy alongside CRO operations.

GENFIT's Q1 2026 royalties surged 243% driven by Ipsen Iqirvo sales reaching €78.8M, securing €136.1M cash and extended runway.

Scilex to distribute 10.7M Semnur shares to shareholders on June 1, creating a standalone public vehicle for the Phase...

Liminatus Pharma acquires InnocsAI's CAR-T pipeline for $320M in stock, adding dual-antigen and solid tumor programs to its oncology...

PharmAla licenses ALA-002 MDMA rights to Jupiter Neurosciences in $100M deal with non-racemic compound gaining FDA Novel Chemical Entity...

Trump's executive orders and IRA negotiations promise relief, but branded drug prices rose 4.5% in 2024 and U.S. drugs...

Scilex to distribute roughly 10.7 million Semnur shares to stockholders while retaining majority control of the pharmaceutical company.

Liminatus Pharma acquires InnocsAI for $320M in all-stock deal to advance bivalent CAR-T oncology programs with dual-antigen targeting.